A Phase 1 interventional study of lagricel ofteno multidose and lagricel ofteno single dose in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-03.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1, and was the 9th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Jin Yang · Sites in China
Beijing Tongren Hospital · Sites in China
Ages 18–65
He Eye Hospital
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2006; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 88 across the 18 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V.: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., this one is the 7th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 1, and was the 7th registered.
Laboratorios Sophia S.A de C.V.’s Dry Eye Syndromes studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Laboratorios Sophia S.A de C.V.’s 13 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
Study design: Phase I clinical trial, single-center, controlled, parallel group, open, randomized.
Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes).
Estimated duration of the study: 5 months
Therapeutic indication: Eye lubricant Use: Dry Eye
Objective:To evaluate the safety and tolerability of Lagricel® Ofteno multidose manufactured by Laboratorios Sophia on the ocular surface of clinically healthy subjects.
Hypothesis:
H0 = Lagricel® Ofteno multidose ophthalmic solution has a safety and tolerability profile similar to Lagricel® Ofteno single dose in healthy subjects.
H1 = Lagricel® Ofteno multidose ophthalmic solution has a different safety and tolerability profile than Lagricel® Ofteno single dose in healthy subjects.
Main inclusion criteria: Clinically healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
Drug: lagricel ofteno multidose
Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
Drug: lagricel ofteno single dose
* Dosage: 1 drop 4 times a day per 7 days, both eyes * Route of administration: Ophthalmic
Also known as: sodium hyaluronate 0.4%
* Dosage: 1 drop 4 times a day per 7 days, both eyes * Route of administration: Ophthalmic
Also known as: sodium hyaluronate 0.4%
Presence of Adverse Events (AEs)
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
Time frame: during the 10 days of evaluation, including the safety call (day 11).
Eye Comfort Index (ECI)
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
Visual Acuity (VA)
Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
Epithelial Defects (ED) Fluorescein Stain
The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
Epithelial Defects (ED) Green Lissamine
The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
Conjunctival Hyperemia (CH)
Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
Chemosis
It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening
Time frame: will be evaluated at the end of the treatment (day 8, final visit)
| Milestone | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Started | 16 | 18 |
| Completed | 16 | 18 |
| Not completed | 0 | 0 |
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
| Participants | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Presence of Adverse Events (AEs) | 7 | 8 |
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).
| score on a scale | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Inicial ECI | 29.98 (20.31 to 39.66) | 27.28 (21.38 to 33.18) |
| Final ECI | 18.76 (12.31 to 25.21) | 18.01 (11.57 to 24.44) |
Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.
| LogMAR | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Final VA | 0.988 ± 0.05 | 0.989 ± 0.05 |
| Initial VA | 0.969 ± 0.09 | 0.989 ± 0.05 |
The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
| Eyes | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Final Fluorescein Staining Grade 0 | 30 | 34 |
| Final Fluorescein Staining Grade 1 | 2 | 2 |
The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
| Eyes | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Final Lissamine Green Staining Grade 0 | 29 | 31 |
| Final Lissamine Green Staining Grade 1 | 3 | 5 |
Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.
| Eyes | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Hyperemia grade 0 (Normal) | 32 | 36 |
| Hyperemia grade 1 (Very Light) | 0 | 0 |
| Hyperemia grade 2 (Light) | 0 | 0 |
| Hyperemia grade 3 (Mild) | 0 | 0 |
| Hyperemia grade 4 (Moderate) | 0 | 0 |
| Hyperemia grade 5 (Severe) | 0 | 0 |
It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening
| Eyes | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| Final chemosis present | 0 | 0 |
| Final chemosis absent | 32 | 36 |
Collected over Adverse events were monitored throughout the study, which lasted about 1 month and 15 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lagricel® Ofteno Multidose | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Lagricel® Ofteno Single Dose | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Event | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose |
|---|---|---|
| burning eyesEye disorders | 4/16 | 5/18 |
| blurred visionEye disorders | 2/16 | 3/18 |
| eye itchingEye disorders | 2/16 | 1/18 |
| dysgeusiaGastrointestinal disorders | 1/16 | 2/18 |
| foreign body sensationEye disorders | 0/16 | 2/18 |
| TearingEye disorders | 1/16 | 0/18 |
| HeadacheNervous system disorders | 1/16 | 1/18 |
| Eye irritationEye disorders | 0/16 | 1/18 |
| Age, Continuous(years) | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose | Total |
|---|---|---|---|
| Mean | 27.8 ± 6.6 | 29.7 ± 7.9 | 29.0 ± 7.33 |
| Sex: Female, Male(Participants) | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose | Total |
|---|---|---|---|
| Female | 12 | 9 | 21 |
| Male | 4 | 9 | 13 |
| Race and Ethnicity Not Collected(Participants) | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Lagricel® Ofteno Multidose | Lagricel® Ofteno Single Dose | Total |
|---|---|---|---|
| Mexico | 16 | 18 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Laboratorios Sophia, S.A. de C.V., serving as the sponsor of the study, assumes full responsibility for its function and retains exclusive ownership rights over the results of the study. The principal investigator undertakes not to publish or communicate data collected from the study, unless there is prior written agreement of Laboratorios Sophia, S.A. de C.V.
Ran from Sep 2019 to primary completion in Oct 2019, 1 month.
Results were first posted in May 2021, 1 year 6 months after primary completion.
Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid
Laboratorios Sophia S.A de C.V. →